Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue (2024 - 2025)

Kura Oncology (KURA) has disclosed Current Deferred Revenue for 2 consecutive years, with $49.0 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 101.82% to $49.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.0 million through Dec 2025, up 101.82% year-over-year, with the annual reading at $49.0 million for FY2025, 101.82% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $49.0 million at Kura Oncology, roughly flat from $48.8 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $49.4 million in Q2 2025, with the low at $24.3 million in Q4 2024.